

Strategic Development of Organometallic Amino Acid Compounds: Design Neurological Therapy

John Hossain*

Department of Biochemistry, University of Nairobi, Nairobi, Kenya

ABOUT THE STUDY

Chemistry, biology, and medicine are deeply interconnected in the design, synthesis, and characterization of organometallic amino acid compounds for neurological applications. These compounds present interesting pathways for regulating biological processes and impacting CNS function because they incorporate metal cores with organic structures. Amino acids possess inherent biological activity, and their incorporation into organometallic structures can enhance their utility in neurological contexts [1]. The design process begins with selecting appropriate metal centers and organic ligands that can interact positively with biological systems. Metals like transition metals, lanthanides, and actinides important due to their ability to form stable complexes and participate in redox reactions, which can be important for neurological applications [2].

In designing these molecules, considerations include the choice of metal, its oxidation state, and the nature of the organic ligand. The metal center must be compatible with biological environments, avoiding toxicity while providing desired therapeutic effects. The organic component, often derived from amino acids, needs to ensure that the resulting organometallic complex can interact effectively with neurological targets [3]. The design must also consider the stability of the organometallic compound, ensuring that it remains intact under physiological conditions and effectively delivers its intended therapeutic benefits.

The synthesis of organometallic amino acid molecules involves multiple steps, beginning with the preparation of the metal complexes. This process typically starts with the formation of a metal-ligand precursor, which is then reacted with amino acids to form the final organometallic product. Synthesis requires precise control over reaction conditions, including temperature, solvent, and concentration, to get high yields and purity of the desired product. Techniques such as ligand exchange, coordination chemistry, and organometallic reactions are commonly used to facilitate the synthesis [4]. One key challenge in synthesis is to get the correct coordination geometry around the metal center. The

three-dimensional arrangement of ligands around the metal can significantly impact the biological activity and stability of the organometallic complex. Moreover, the synthesis must be scalable and reproducible to ensure that sufficient quantities of the organometallic amino acid molecules can be produced for further testing and development [5].

Characterization is an important step in the development of organometallic amino acid molecules. It involves confirming the structure, purity, and stability of the synthesized compounds using various analytical techniques [6]. Techniques such as Nuclear Magnetic Resonance (NMR) spectroscopy, mass spectrometry, and X-ray crystallography provide detailed information about the molecular structure and confirm the presence of the desired metal-ligand interactions. These techniques help in analyzing the coordination and the conformation of the organic ligand [7]. In addition to structural characterization, physicochemical properties such as solubility, stability, and reactivity in biological environments are analyzed. These properties are important for evaluating the potential efficacy and safety of the organometallic amino acid molecules in neurological applications. The way the chemicals react in a biological setting is determined through stability tests conducted under physiological settings, such as changes in pH and temperature [8].

Biological characterization follows the structural and physicochemical analysis. This involves evaluating the interaction of the organometallic molecules with biological targets, such as neural cells or receptors. Techniques such as cell viability, binding studies, and imaging methods are used to assess the biological activity of the compounds [9]. The integration of organometallic amino acid molecules into neurological applications provides a range of possibilities. Their ability to modulate biological processes through metal-based mechanisms can lead to novel treatments for neurological disorders. For instance, these molecules might influence neurotransmitter systems, protect against oxidative stress, or modulate ion channels, all of which are relevant to neurological function [10]. The design and characterization of these compounds are important for realizing

Correspondence to: John Hossain, Department of Biochemistry, University of Nairobi, Nairobi, Kenya, E-mail: hossain888@gmail.com

Received: 27-May-2024, Manuscript No. BCPC-24-33164; **Editor assigned:** 30-May-2024, PreQC No. BCPC-24-33164 (PQ); **Reviewed:** 14-Jun-2024, QC No. BCPC-24-33164; **Revised:** 21-Jun-2024, Manuscript No. BCPC-24-33164 (R); **Published:** 28-Jun-2024, DOI: 10.35248/2167-0501.24.13.359

Citation: Hossain J (2024) Strategic Development of Organometallic Amino Acid Compounds: Design Neurological Therapy. *Biochem Pharmacol.* 13:359.

Copyright: © 2024 Hossain J. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

their full therapeutic potential and ensuring that they provide beneficial effects without unwanted side effects.

REFERENCES

1. Nakaya Y, Hirayama J, Yamazoe S, Shimizu KI, Furukawa S. Single-atom Pt in intermetallics as an ultrastable and selective catalyst for propane dehydrogenation. *Nat Commun.* 2020;11(1):2838.
2. Bickelhaupt FM, Guerra CF, Mitoraj M, Sagan F, Michalak A, Pan S, et al. Clarifying notes on the bonding analysis adopted by the energy decomposition analysis. *Phys Chem Chem Phys.* 2022;24(26):15726-15735.
3. Goesten MG, Hoffmann R, Bickelhaupt FM, Hensen EJ. Eight-coordinate fluoride in a silicate double-four-ring. *Proc Natl Acad Sci.* 2017;114(5):828-833.
4. Michalak A, DeKock RL, Ziegler T. Bond multiplicity in transition-metal complexes: Applications of two-electron valence indices. *J Phys Chem A.* 2008;112(31):7256-7263.
5. Fonseca Guerra C, Handgraaf JW, Baerends EJ, Bickelhaupt FM. Voronoi Deformation Density (VDD) charges: Assessment of the Mulliken, Bader, Hirshfeld, Weinhold, and VDD methods for charge analysis. *J Comput Chem.* 2004;25(2):189-210.
6. Sowlati-Hashjin S, Sadek V, Sadjadi S, Karttunen M, Martin-Pendas A, Foroutan-Nejad C. Collective interactions among organometallics are exotic bonds hidden on lab shelves. *Nat Commun.* 2022;13(1):2069.
7. Yunker LP, Stoddard RL, McIndoe JS. Practical approaches to the ESI-MS analysis of catalytic reactions. *J Mass Spectrom.* 2014;49(1):1-8.
8. Welker M. Proteomics for routine identification of microorganisms. *Proteomics.* 2011;11(15):3143-3153.
9. Soltwisch J, Jaskolla TW, Hillenkamp F, Karas M, Dreisewerd K. Ion yields in UV-MALDI mass spectrometry as a function of excitation laser wavelength and optical and physico-chemical properties of classical and halogen-substituted MALDI matrixes. *Anal Chem.* 2012;84(15):6567-6576.
10. Ingram AJ, Boeser CL, Zare RN. Going beyond electrospray: Mass spectrometric studies of chemical reactions in and on liquids. *Chem Sci.* 2016;7(1):39-55.